- Home
- NGS vs ETON Comparison
NGS vs ETON Comparison
Compare NGS & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGS
- ETON
- Stock Information
- Founded
- NGS 1998
- ETON 2017
- Country
- NGS United States
- ETON United States
- Employees
- NGS N/A
- ETON N/A
- Industry
- NGS Oilfield Services/Equipment
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- NGS Energy
- ETON Health Care
- Exchange
- NGS Nasdaq
- ETON Nasdaq
- Market Cap
- NGS N/A
- ETON 428.5M
- IPO Year
- NGS 2002
- ETON 2018
- Fundamental
- Price
- NGS $20.11
- ETON $17.33
- Analyst Decision
- NGS Strong Buy
- ETON Strong Buy
- Analyst Count
- NGS 1
- ETON 3
- Target Price
- NGS $32.00
- ETON $27.67
- AVG Volume (30 Days)
- NGS 71.1K
- ETON 221.4K
- Earning Date
- NGS 05-12-2025
- ETON 05-13-2025
- Dividend Yield
- NGS N/A
- ETON N/A
- EPS Growth
- NGS 260.53
- ETON N/A
- EPS
- NGS 1.37
- ETON N/A
- Revenue
- NGS $156,742,000.00
- ETON $39,011,000.00
- Revenue This Year
- NGS $12.87
- ETON $92.33
- Revenue Next Year
- NGS $15.40
- ETON $52.62
- P/E Ratio
- NGS $14.68
- ETON N/A
- Revenue Growth
- NGS 29.36
- ETON 23.29
- 52 Week Low
- NGS $16.70
- ETON $3.18
- 52 Week High
- NGS $29.74
- ETON $18.41
- Technical
- Relative Strength Index (RSI)
- NGS 53.74
- ETON 68.29
- Support Level
- NGS $17.63
- ETON $16.43
- Resistance Level
- NGS $19.68
- ETON $17.49
- Average True Range (ATR)
- NGS 1.00
- ETON 0.88
- MACD
- NGS 0.28
- ETON 0.19
- Stochastic Oscillator
- NGS 90.51
- ETON 92.78
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.